Targeting SARM1 and Axon Degeneration as a Design-Modifying Strategy for the Treatment of CMT2A
48:52
Can SARM1 Removal Lead to a Therapy for CMT2A Patients?
1:13:23
CMT1A Clinical Trial and Drug Development Update
1:09:20
OHio, What a Night: Lighting a Path to a Cure for Charcot-Marie-Tooth Disease
16:58
Targeting Cytosolic HDAC6 Inhibition for the Treatment of CMT and Beyond
28:28